Stifel Nicolaus Raises Precigen (NASDAQ:PGEN) Price Target to $10.00

Precigen (NASDAQ:PGEN) had its price target boosted by Stifel Nicolaus from $7.00 to $10.00 in a research report sent to investors on Monday morning, Benzinga reports. They currently have a buy rating on the biotechnology company’s stock.

Several other analysts also recently commented on the stock. HC Wainwright reissued a buy rating and issued a $6.00 target price on shares of Precigen in a research report on Monday. JPMorgan Chase & Co. downgraded shares of Precigen from a neutral rating to an underweight rating in a report on Friday, March 22nd. StockNews.com raised shares of Precigen to a sell rating in a report on Tuesday, May 21st. Cantor Fitzgerald reaffirmed an overweight rating on shares of Precigen in a report on Wednesday, May 15th. Finally, JMP Securities reaffirmed a market outperform rating and set a $14.00 price objective on shares of Precigen in a report on Wednesday, March 20th. Two investment analysts have rated the stock with a sell rating and four have given a buy rating to the stock. Based on data from MarketBeat.com, Precigen has a consensus rating of Hold and an average price target of $10.00.

Precigen Stock Up 6.1 %

PGEN stock opened at $1.75 on Monday. The company has a market capitalization of $441.74 million, a price-to-earnings ratio of -4.49 and a beta of 1.88. Precigen has a 12 month low of $0.84 and a 12 month high of $1.88. The firm has a 50 day moving average of $1.40 and a two-hundred day moving average of $1.37.

Precigen (NASDAQ:PGEN) last posted its earnings results on Tuesday, May 14th. The biotechnology company reported ($0.10) EPS for the quarter, missing the consensus estimate of ($0.09) by ($0.01). The business had revenue of $1.07 million during the quarter, compared to the consensus estimate of $1.54 million. Precigen had a negative return on equity of 65.36% and a negative net margin of 1,781.72%. During the same period in the prior year, the firm earned ($0.10) earnings per share. On average, research analysts expect that Precigen will post -0.36 EPS for the current fiscal year.

Institutional Trading of Precigen

Large investors have recently modified their holdings of the company. SG Americas Securities LLC boosted its holdings in Precigen by 12.5% in the 4th quarter. SG Americas Securities LLC now owns 76,352 shares of the biotechnology company’s stock valued at $102,000 after purchasing an additional 8,478 shares during the period. Fortis Group Advisors LLC bought a new stake in Precigen in the 1st quarter valued at $28,000. China Universal Asset Management Co. Ltd. boosted its holdings in Precigen by 66.1% in the 1st quarter. China Universal Asset Management Co. Ltd. now owns 47,829 shares of the biotechnology company’s stock valued at $69,000 after purchasing an additional 19,041 shares during the period. Vanguard Group Inc. boosted its holdings in Precigen by 0.3% in the 1st quarter. Vanguard Group Inc. now owns 6,768,234 shares of the biotechnology company’s stock valued at $9,814,000 after purchasing an additional 19,875 shares during the period. Finally, EntryPoint Capital LLC bought a new stake in Precigen in the 1st quarter valued at $31,000. 33.51% of the stock is owned by institutional investors.

Precigen Company Profile

Precigen, Inc operates as a discovery and clinical-stage biopharmaceutical company that develops gene and cell therapies using precision technology to target diseases in therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. It operates through two segments, Biopharmaceuticals and Exemplar.